Flooring system meets challenges at vaccine pilot plant

This white paper by Sherwin-Williams Co. describes flooring challenges at vaccine pilot plants in the pharmaceutical industry. As a major building component, the flooring system and its ability to perform under harsh conditions have a critical impact on day-to-day operations in the manufacture of pharmaceuticals or, in this case, vaccines. Building material for pharmaceutical manufacturing has many unique requirements that set it apart from other industries. In the case of the vaccine plant described, exhaustive measures were taken to assure that federal current Good Manufacturing Practices (cGMP) regulations were strictly followed.

Like many other pharmaceutical sites, this particular plant has a concrete floor, and any coating must resist most acids, oils, solvents and cleaning solutions. Floor coatings selected for these facilities must be durable and thick enough to create a protective barrier that prevents contaminants from permeating the concrete substrate and ensures a hygienic surface.

• Email This Page
• Print This Page